Morrison Maura A, Artru Florent, Trovato Francesca M, Triantafyllou Evangelos, McPhail Mark J
Institute of Liver Studies, King's College Hospital, London, UK.
Department of Inflammation Biology, School of Immunology and Microbial Sciences, King's College London, London, UK.
Liver Int. 2025 Mar;45(3):e15545. doi: 10.1111/liv.15545. Epub 2023 Mar 8.
Acute-on-chronic liver failure (ACLF) is a syndrome that develops in approximately 30% of patients hospitalised with cirrhosis and is characterised by an acute decompensation of liver function associated with extra-hepatic organ failures and a high short-term mortality. At present, no specific therapies are available for ACLF, and current management is limited to treatment of the precipitating event and organ support. Given the high prevalence and high mortality of this severe liver disease, there is an urgent need for targeted treatments. There is increasing evidence of the important role played by systemic inflammation and immune dysfunction in the pathophysiology of ACLF and a better understanding of these immune processes is resulting in new therapeutic targets. The aim of this review is to present an overview of ongoing studies of potentially promising therapies and how they could be utilised in the management of ACLF.
慢加急性肝衰竭（ACLF）是一种综合征，约30%因肝硬化住院的患者会发生该综合征，其特征为肝功能急性失代偿，伴有肝外器官功能衰竭，且短期死亡率高。目前，尚无针对ACLF的特异性疗法，当前的治疗仅限于对诱发事件的处理和器官支持。鉴于这种严重肝病的高发病率和高死亡率，迫切需要有针对性的治疗方法。越来越多的证据表明全身炎症和免疫功能障碍在ACLF的病理生理学中发挥着重要作用，对这些免疫过程的更好理解正催生出新的治疗靶点。本综述的目的是概述正在进行的关于潜在有前景疗法的研究，以及这些疗法如何用于ACLF的管理。
